Circadian clock: Time for novel anticancer strategies?

Pharmacological Research

Volumn 100, Issue , 2015, Pages 288-295

  Ercolani, Luisa ^a   Ferrari, Alessio ^a   Mei, Claudia De ^a   Parodi, Chiara ^a   Wade, Mark ^a   Grimaldi, Benedetto ^a  

^a ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

Author keywords

Anticancer agents; ARN5187; Autophagy; Cancer; Circadian; Combined anticancer strategy; Dual inhibitor; Lysosomotropic agents; Metabolism; Nuclear receptors; REV ERB; REV ERB agonist; REV ERB antagonist; SR9011

Indexed keywords

ANTINEOPLASTIC AGENT; ARN 5187; AZD 3965; CELL NUCLEUS RECEPTOR; CHLOROQUINE; CYCLIN A2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GSK 2945; GSK 4112; NUCLEAR RECEPTOR NR1D1; PROTEIN KINASE B; PROTEIN REV ERB BETA; REV ERB AGONIST; SR 9009; SR 9011; TRANSCRIPTION FACTOR ARNTL; TRANSCRIPTION FACTOR CLOCK; UNCLASSIFIED DRUG; CELL RECEPTOR; MOLECULAR LIBRARY;

APOPTOSIS; AUTOPHAGY; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CARCINOGENESIS; CELL SURVIVAL; CIRCADIAN RHYTHM; DISEASE ASSOCIATION; DOWN REGULATION; DRUG MECHANISM; DRUG POTENCY; DRUG SPECIFICITY; DRUG STRUCTURE; GENE EXPRESSION REGULATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RNA INTERFERENCE; TRANSCRIPTION REGULATION; ANIMAL; DRUG EFFECTS; GENETICS; MOLECULAR LIBRARY; NEOPLASMS; PHARMACOLOGY; THERAPEUTIC USE;

ANIMALS; ANTINEOPLASTIC AGENTS; CIRCADIAN CLOCKS; CIRCADIAN RHYTHM; HUMANS; NEOPLASMS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SMALL MOLECULE LIBRARIES;

EID: 84941350071     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2015.08.008     Document Type: Review

References (71)

1. C. Dibner, U. Schibler, and U. Albrecht The mammalian circadian timing system: organization and coordination of central and peripheral clocks Annu. Rev. Physiol. 72 2010 517 549
2. U.P. Schiblerand, and P. Sassone-Corsi A web of circadian pacemakers Cell 111 2002 919 922
3. C.H. Ko, and J.S. Takahashi Molecular components of the mammalian circadian clock Hum. Mol. Genet. 15 2006 R271 R277 Spec No. 2
4. C. Saini, S.A. Brown, and C. Dibner Human peripheral clocks: applications for studying circadian phenotypes in physiology and pathophysiology Front. Neurol. 6 2015 95
5. B. Grimaldi, Y. Nakahata, M. Kaluzova, S. Masubuchi, and P. Sassone-Corsi Chromatin remodeling, metabolism and circadian clocks: the interplay of CLOCK and SIRT1 Int. J. Biochem. Cell Biol. 41 2009 81 86
6. J. Richards, and M.L. Gumz Mechanism of the circadian clock in physiology Am. J. Physiol. Regul. Integr. Comp. Physiol. 304 2013 R1053 R1064
7. P.E. Hardin, and S. Panda Circadian timekeeping and output mechanisms in animals Curr. Opin. Neurobiol. 23 2013 724 731
8. F.D. Gachon, and D. Firsov The role of circadian timing system on drug metabolism and detoxification Expert Opin. Drug Metab. Toxicol. 7 2011 147 158
9. P.F. Innominato, V.P. Roche, O.G. Palesh, A. Ulusakarya, D. Spiegel, and F.A. Levi The circadian timing system in clinical oncology Ann. Med. 46 2014 191 207
10. M.H. Hastings, A.B. Reddy, and E.S. Maywood A clockwork web: circadian timing in brain and periphery, in health and disease Nat. Rev. Neurosci. 4 2003 649 661
11. S. Rossetti, J. Esposito, F. Corlazzoli, A. Gregorski, and N. Sacchi Entrainment of breast (cancer) epithelial cells detects distinct circadian oscillation patterns for clock and hormone receptor genes Cell Cycle 11 2012 350 360
12. Y. Jia, Y. Lu, K. Wu, Q. Lin, W. Shen, M. Zhu, S. Huang, and J. Chen Does night work increase the risk of breast cancer? A systematic review and meta-analysis of epidemiological studies Cancer Epidemiol. 37 2013 197 206
13. M. Teboul, F. Guillaumond, A. Grechez-Cassiau, and F. Delaunay The nuclear hormone receptor family round the clock Mol. Endocrinol. 22 2008 2573 2582
14. S. Raghuram, K.R. Stayrook, P. Huang, P.M. Rogers, A.K. Nosie, D.B. McClure, L.L. Burris, S. Khorasanizadeh, T.P. Burris, and F. Rastinejad Identification of heme as the ligand for the orphan nuclear receptors REV-ERBα and REV-ERBβ Nat. Struct. Mol. Biol. 14 2007 1207 1213
15. H. Cho, X. Zhao, M. Hatori, R.T. Yu, G.D. Barish, M.T. Lam, L.W. Chong, L. DiTacchio, A.R. Atkins, C.K. Glass, C. Liddle, J. Auwerx, M. Downes, S. Panda, and R.M. Evans Regulation of circadian behaviour and metabolism by REV-ERB-α and REV-ERB-β Nature 485 2012 123 127
16. A. Bugge, D. Feng, L.J. Everett, E.R. Briggs, S.E. Mullican, F. Wang, J. Jager, and M.A. Lazar Rev-erbα and Rev-erbβ coordinately protect the circadian clock and normal metabolic function Genes Dev. 26 2012 657 667
17. D. Grant, L. Yin, J.L. Collins, D.J. Parks, L.A. Orband-Miller, G.B. Wisely, S. Joshi, M.A. Lazar, T.M. Willson, and W.J. Zuercher GSK4112, a small molecule chemical probe for the cell biology of the nuclear heme receptor Rev-erbα ACS Chem. Biol. 5 2010 925 932
18. N. Kumar, L.A. Solt, Y. Wang, P.M. Rogers, G. Bhattacharyya, T.M. Kamenecka, K.R. Stayrook, C. Crumbley, Z.E. Floyd, J.M. Gimble, P.R. Griffin, and T.P. Burris Regulation of adipogenesis by natural and synthetic REV-ERB ligands Endocrinology 151 2010 3015 3025
19. L.A. Solt, Y. Wang, S. Banerjee, T. Hughes, D.J. Kojetin, T. Lundasen, Y. Shin, J. Liu, M.D. Cameron, R. Noel, S.H. Yoo, J.S. Takahashi, A.A. Butler, T.M. Kamenecka, and T.P. Burris Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists Nature 485 2012 62 68
20. C. Hong, and P. Tontonoz Liver X receptors in lipid metabolism: opportunities for drug discovery Nat. Rev. Drug Discov. 13 2014 433 444
21. K.R. Steffensen, T. Jakobsson, and J.A. Gustafsson Targeting liver X receptors in inflammation Expert Opin. Ther. Targets 17 2013 977 990
22. R.P. Trump, S. Bresciani, A.W. Cooper, J.P. Tellam, J. Wojno, J. Blaikley, L.A. Orband-Miller, J.A. Kashatus, M. Boudjelal, H.C. Dawson, A. Loudon, D. Ray, D. Grant, S.N. Farrow, T.M. Willson, and N.C. Tomkinson Optimized chemical probes for REV-ERBα J. Med. Chem. 56 2013 4729 4737
23. D. Kojetin, Y. Wang, T.M. Kamenecka, and T.P. Burris Identification of SR8278, a synthetic antagonist of the nuclear heme receptor REV-ERB ACS Chem. Biol. 6 2011 131 134
24. E. Torrente, C. Parodi, L. Ercolani, C. De Mei, A. Ferrari, R. Scarpelli, and B. Grimaldi Synthesis and in vitro anticancer activity of the first class of dual inhibitors of REV-ERBβ and autophagy J. Med. Chem. 58 2015 5900 5915
25. M.A. Lazar, K.E. Jones, and W.W. Chin Isolation of a cDNA encoding human Rev-ErbA alpha: transcription from the noncoding DNA strand of a thyroid hormone receptor gene results in a related protein that does not bind thyroid hormone DNA Cell Biol. 9 1990 77 83
26. M.M. Reinholz, A.K. Bruzek, D.W. Visscher, W.L. Lingle, M.J. Schroeder, E.A. Perez, and R.B. Jenkins Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response Lancet Oncol. 10 2009 267 277
27. B. Orsetti, F. Courjal, M. Cuny, C. Rodriguez, and C. Theillet 17q21-q25 aberrations in breast cancer: combined allelotyping and CGH analysis reveals 5 regions of allelic imbalance among which two correspond to DNA amplification Oncogene 18 1999 6262 6270
28. B. Orsetti, M. Nugoli, N. Cervera, L. Lasorsa, P. Chuchana, L. Ursule, C. Nguyen, R. Redon, S. du Manoir, C. Rodriguez, and C. Theillet Genomic and expression profiling of chromosome 17 in breast cancer reveals complex patterns of alterations and novel candidate genes Cancer Res. 64 2004 6453 6460
29. C. De Mei, L. Ercolani, C. Parodi, M. Veronesi, C. Lo Vecchio, G. Bottegoni, E. Torrente, R. Scarpelli, R. Marotta, R. Ruffili, M. Mattioli, A. Reggiani, M. Wade, and B. Grimaldi Dual inhibition of REV-ERBβ and autophagy as a novel pharmacological approach to induce cytotoxicity in cancer cells Oncogene 34 2015 2597 2608
30. L. Chen, Y. Shi, S. Liu, Y. Cao, X. Wang, and Y. Tao PKM2: the thread linking energy metabolism reprogramming with epigenetics in cancer Int. J. Mol. Sci. 15 2014 11435 11445
31. A. Kourtidis, R. Jain, R.D. Carkner, C. Eifert, M.J. Brosnan, and D.S. Conklin An RNA interference screen identifies metabolic regulators NR1D1 and PBP as novel survival factors for breast cancer cells with the ERBB2 signature Cancer Res. 70 2010 1783 1792
32. K.K. Sahlberg, V. Hongisto, H. Edgren, R. Makela, K. Hellstrom, E.U. Due, H.K. Moen Vollan, N. Sahlberg, M. Wolf, A.L. Borresen-Dale, M. Perala, and O. Kallioniemi The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells Mol. Oncol. 7 2013 392 401
33. M. Tanner, A.I. Kapanen, T. Junttila, O. Raheem, S. Grenman, J. Elo, K. Elenius, and J. Isola Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer Mol. Cancer Ther. 3 2004 1585 1592
34. D.R. Green, and B. Levine To be or not to be? How selective autophagy and cell death govern cell fate Cell 157 2014 65 75
35. G. Marino, M. Niso-Santano, E.H. Baehrecke, and G. Kroemer Self-consumption: the interplay of autophagy and apoptosis Nat. Rev. Mol. Cell Biol. 15 2014 81 94
36. H. Cheong, C. Lu, T. Lindsten, and C.B. Thompson Therapeutic targets in cancer cell metabolism and autophagy Nat. Biotechnol. 30 2012 671 678
37. J.S. Carew, K.R. Kelly, and S.T. Nawrocki Autophagy as a target for cancer therapy: new developments Cancer Manag. Res. 4 2012 357 365
38. S. Nadanaciva, S. Lu, D.F. Gebhard, B.A. Jessen, W.D. Pennie, and Y. Will A high content screening assay for identifying lysosomotropic compounds Toxicol. In Vitro 25 2011 715 723
39. L. Fu, and N.M. Kettner The circadian clock in cancer development and therapy Prog. Mol. Biol. Transl. Sci. 119 2013 221 282
40. Q. McAfee, Z. Zhang, A. Samanta, S.M. Levi, X.H. Ma, S. Piao, J.P. Lynch, T. Uehara, A.R. Sepulveda, L.E. Davis, J.D. Winkler, and R.K. Amaravadi Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency Proc. Natl. Acad. Sci. U. S. A. 109 2012 8253 8258
41. T. Kimura, Y. Takabatake, A. Takahashi, and Y. Isaka Chloroquine in cancer therapy: a double-edged sword of autophagy Cancer Res. 73 2013 3 7
42. H. Duez, and B. Staels Rev-erb-α: an integrator of circadian rhythms and metabolism J. Appl. Physiol. 107 2009 1972 1980
43. D.A. Tennant, R.V. Duran, and E. Gottlieb Targeting metabolic transformation for cancer therapy Nat. Rev. Cancer 10 2010 267 277
44. Y. Wang, D. Kojetin, and T.P. Burris Anti-proliferative actions of a synthetic REV-ERBα/β agonist in breast cancer cells Biochem. Pharmacol. 96 2015 315 322
45. L. Gopinathan, S.L. Tan, V.C. Padmakumar, V. Coppola, L. Tessarollo, and P. Kaldis Loss of Cdk2 and cyclin A2 impairs cell proliferation and tumorigenesis Cancer Res. 74 2014 3870 3879
46. C.Y. Lin, and J.A. Gustafsson Targeting liver X receptors in cancer therapeutics Nat. Rev. Cancer 15 2015 216 224
47. J.C. Lucchesi Synthetic lethality and semi-lethality among functionally related mutants of Drosophila melanfgaster Genetics 59 1968 37 44
48. R.J. Konopka, and S. Benzer Clock mutants of Drosophila melanogaster Proc. Natl. Acad. Sci. U. S. A. 68 1971 2112 2116
49. S. Sathyanarayanan, X. Zheng, S. Kumar, C.H. Chen, D. Chen, B. Hay, and A. Sehgal Identification of novel genes involved in light-dependent CRY degradation through a genome-wide RNAi screen Genes Dev. 22 2008 1522 1533
50. G. Dietzl, D. Chen, F. Schnorrer, K.C. Su, Y. Barinova, M. Fellner, B. Gasser, K. Kinsey, S. Oppel, S. Scheiblauer, A. Couto, V. Marra, K. Keleman, and B.J. Dickson A genome-wide transgenic RNAi library for conditional gene inactivation in Drosophila Nature 448 2007 151 156
51. E.E. Zhang, A.C. Liu, T. Hirota, L.J. Miraglia, G. Welch, P.Y. Pongsawakul, X. Liu, A. Atwood, J.W. Huss 3rd, J. Janes, A.I. Su, J.B. Hogenesch, and S.A. Kay A genome-wide RNAi screen for modifiers of the circadian clock in human cells Cell 139 2009 199 210
52. B. Maier, S. Wendt, J.T. Vanselow, T. Wallach, S. Reischl, S. Oehmke, A. Schlosser, and A. Kramer A large-scale functional RNAi screen reveals a role for CK2 in the mammalian circadian clock Genes Dev. 23 2009 708 718
53. J.L. Price, J.Y. Fan, A. Keightley, and J.C. Means The role of casein kinase I in the Drosophila circadian clock Methods Enzymol. 551 2015 175 195
54. M. Toyoshima, H.L. Howie, M. Imakura, R.M. Walsh, J.E. Annis, A.N. Chang, J. Frazier, B.N. Chau, A. Loboda, P.S. Linsley, M.A. Cleary, J.R. Park, and C. Grandori Functional genomics identifies therapeutic targets for MYC-driven cancer Proc. Natl. Acad. Sci. U. S. A. 109 2012 9545 9550
55. W.S. Yang, and B.R. Stockwell Inhibition of casein kinase 1-epsilon induces cancer-cell-selective, PERIOD2-dependent growth arrest Genome Biol. 9 2008 R92
56. D.J. Kennaway, T.J. Varcoe, A. Voultsios, M.D. Salkeld, L. Rattanatray, and M.J. Boden Acute inhibition of casein kinase 1delta/epsilon rapidly delays peripheral clock gene rhythms Mol. Cell. Biochem. 398 2015 195 206
57. Y. Zheng, B.C. McFarland, D. Drygin, H. Yu, S.L. Bellis, H. Kim, M. Bredel, and E.N. Benveniste Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastoma Clin. Cancer Res. 19 2013 6484 6494
58. B. Qin, K. Minter-Dykhouse, J. Yu, J. Zhang, T. Liu, H. Zhang, S. Lee, J. Kim, L. Wang, and Z. Lou DBC1 functions as a tumor suppressor by regulating p53 stability Cell Rep. 10 2015 1324 1334
59. C.C. Chini, C. Escande, V. Nin, and E.N. Chini DBC1 (deleted in breast cancer 1) modulates the stability and function of the nuclear receptor Rev-erbα Biochem. J. 451 2013 453 461
60. L. Yin, J. Wang, P.S. Klein, and M.A. Lazar Nuclear receptor Rev-erbα is a critical lithium-sensitive component of the circadian clock Science 311 2006 1002 1005
61. L. Yin, S. Joshi, N. Wu, X. Tong, and M.A. Lazar E3 ligases Arf-bp1 and Pam mediate lithium-stimulated degradation of the circadian heme receptor Rev-erb α Proc. Natl. Acad. Sci. U. S. A. 107 2010 11614 11619
62. J. Luo, M.J. Emanuele, D. Li, C.J. Creighton, M.R. Schlabach, T.F. Westbrook, K.K. Wong, and S.J. Elledge A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene Cell 137 2009 835 848
63. R. Polanski, C.L. Hodgkinson, A. Fusi, D. Nonaka, L. Priest, P. Kelly, F. Trapani, P.W. Bishop, A. White, S.E. Critchlow, P.D. Smith, F. Blackhall, C. Dive, and C.J. Morrow Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer Clin. Cancer Res. 20 2014 926 937
64. A.T. Stearns, A. Balakrishnan, D.B. Rhoads, S.W. Ashley, and A. Tavakkolizadeh Diurnal rhythmicity in the transcription of jejunal drug transporters J. Pharmacol. Sci. 108 2008 144 148
65. M.A. Iqbal, V. Gupta, P. Gopinath, S. Mazurek, and R.N. Bamezai Pyruvate kinase M2 and cancer: an updated assessment FEBS Lett. 588 2014 2685 2692
66. H. Wu, Z. Li, P. Yang, L. Zhang, Y. Fan, and Z. Li PKM2 depletion induces the compensation of glutaminolysis through beta-catenin/c-Myc pathway in tumor cells Cell Signal. 26 2014 2397 2405
67. D.K. Daye, and K.E. Wellen Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis Semin. Cell Dev. Biol. 23 2012 362 369
68. M.H. Kim, and H. Kim Oncogenes and tumor suppressors regulate glutamine metabolism in cancer cells J. Cancer Prev. 18 2013 221 226
69. A. Huang, B. Bao, H.R. Gaskins, H. Liu, X. Zhang, L. Lu, S. Gao, Y. Shi, M. Zhang, Y. Shan, J. Feng, and G. Yao Circadian clock gene expression regulates cancer cell growth through glutaminase Acta Biochim. Biophys. Sin. 46 2014 409 414
70. J.H. Lee, and A. Sancar Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis Proc. Natl. Acad. Sci. U. S. A. 108 2011 10668 10672
71. S.K. Chun, J. Jang, S. Chung, H. Yun, N.J. Kim, J.W. Jung, G.H. Son, Y.G. Suh, and K. Kim Identification and validation of cryptochrome inhibitors that modulate the molecular circadian clock ACS Chem. Biol. 9 2014 703 710